Tute Genomics has raised $2.3 million in Series A1 funding round led by UK-based Eurovestech, with participation from Peak Ventures, and a number of angel investors.

The company has developed a cloud-based genome analytics platform that empowers clinicians and researchers to draw meaningful insights from genome sequencing data. The ease of use and power of Tute’s software gives labs, clinicians and researchers the ability to unlock the genome, personalize treatment and power discovery.

“One of the main barriers to making personalized, genome-guided medicine a reality is data analysis, and Tute’s platform drastically decreases the complexity and cost of analyzing genomic data sets,” said Reid Robison, MD MBA, CEO of Tute Genomics. “With the support of our new and existing investors, this financing will help us achieve our goal of transforming healthcare by bringing genomic insights into routine medical practice.”

Nearly 10,000 samples have already been processed by the platform, and Tute has commercial agreements in place across numerous institutions including clinical labs, molecular diagnostic companies, and research institutions.